 Nancy Madinger
Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trench Fever | 1 | 2022 | 5 | 0.810 |
Why?
| | Bartonella quintana | 1 | 2022 | 5 | 0.810 |
Why?
| | Endocarditis | 1 | 2022 | 38 | 0.770 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 196 | 0.630 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.520 |
Why?
| | Strongyloidiasis | 1 | 2016 | 4 | 0.520 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.520 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 20 | 0.510 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.500 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.500 |
Why?
| | Anemia | 1 | 2016 | 161 | 0.460 |
Why?
| | Sexual Behavior | 1 | 2019 | 481 | 0.460 |
Why?
| | Program Evaluation | 1 | 2019 | 877 | 0.460 |
Why?
| | Carbapenems | 1 | 2014 | 23 | 0.440 |
Why?
| | Klebsiella Infections | 1 | 2014 | 25 | 0.440 |
Why?
| | Klebsiella pneumoniae | 1 | 2014 | 42 | 0.440 |
Why?
| | beta-Lactamases | 1 | 2014 | 41 | 0.430 |
Why?
| | Rectum | 1 | 2014 | 170 | 0.400 |
Why?
| | Curriculum | 1 | 2019 | 925 | 0.390 |
Why?
| | Disease Outbreaks | 1 | 2014 | 349 | 0.350 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2021 | 72 | 0.330 |
Why?
| | Internship and Residency | 1 | 2019 | 1052 | 0.320 |
Why?
| | Methicillin | 1 | 2009 | 11 | 0.310 |
Why?
| | Anti-Bacterial Agents | 6 | 2021 | 1708 | 0.310 |
Why?
| | Platelet Transfusion | 1 | 2009 | 61 | 0.290 |
Why?
| | HIV Infections | 2 | 2022 | 2730 | 0.290 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 205 | 0.290 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 175 | 0.260 |
Why?
| | Enterobacteriaceae | 2 | 2021 | 39 | 0.250 |
Why?
| | Immunoglobulin G | 2 | 2022 | 851 | 0.240 |
Why?
| | Rhizopus | 1 | 2005 | 5 | 0.240 |
Why?
| | Blood Platelets | 1 | 2009 | 386 | 0.240 |
Why?
| | Facial Pain | 1 | 2005 | 13 | 0.240 |
Why?
| | Mucormycosis | 1 | 2005 | 22 | 0.240 |
Why?
| | Staphylococcus aureus | 1 | 2009 | 436 | 0.230 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.220 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 402 | 0.220 |
Why?
| | Mycoses | 1 | 2003 | 73 | 0.210 |
Why?
| | Sinusitis | 1 | 2005 | 211 | 0.200 |
Why?
| | Brain Diseases | 1 | 2003 | 134 | 0.200 |
Why?
| | Peptide Nucleic Acids | 1 | 2021 | 4 | 0.180 |
Why?
| | Enterobacteriaceae Infections | 1 | 2021 | 41 | 0.170 |
Why?
| | Cross Infection | 2 | 2009 | 217 | 0.170 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 112 | 0.170 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.170 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 19 | 0.170 |
Why?
| | Bacteria | 2 | 2017 | 814 | 0.170 |
Why?
| | Cryptococcosis | 1 | 2020 | 26 | 0.170 |
Why?
| | Drug Design | 1 | 2021 | 158 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 5 | 2021 | 349 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2005 | 576 | 0.160 |
Why?
| | Antifungal Agents | 3 | 2020 | 130 | 0.150 |
Why?
| | Female | 14 | 2022 | 68751 | 0.140 |
Why?
| | Humans | 25 | 2022 | 129687 | 0.140 |
Why?
| | Superoxides | 1 | 2017 | 201 | 0.130 |
Why?
| | Adult | 10 | 2020 | 35607 | 0.130 |
Why?
| | Computational Biology | 1 | 2021 | 594 | 0.130 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.130 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.130 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.130 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.130 |
Why?
| | Ivermectin | 1 | 2016 | 13 | 0.130 |
Why?
| | Xanthomonas | 1 | 1996 | 2 | 0.130 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2009 | 221 | 0.130 |
Why?
| | Hematocrit | 1 | 2016 | 93 | 0.130 |
Why?
| | Acinetobacter | 1 | 1996 | 13 | 0.130 |
Why?
| | Pseudomonas | 1 | 1996 | 28 | 0.130 |
Why?
| | Praziquantel | 1 | 2015 | 5 | 0.120 |
Why?
| | Anthelmintics | 1 | 2015 | 10 | 0.120 |
Why?
| | Quantum Dots | 1 | 2016 | 34 | 0.120 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1996 | 45 | 0.120 |
Why?
| | Middle Aged | 8 | 2022 | 31165 | 0.120 |
Why?
| | Feces | 2 | 2015 | 442 | 0.120 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 757 | 0.120 |
Why?
| | Male | 12 | 2022 | 63691 | 0.120 |
Why?
| | o-Phthalaldehyde | 1 | 2014 | 3 | 0.120 |
Why?
| | Migraine Disorders | 1 | 2016 | 101 | 0.110 |
Why?
| | Glutaral | 1 | 2014 | 15 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1994 | 27 | 0.110 |
Why?
| | Disinfectants | 1 | 2014 | 35 | 0.110 |
Why?
| | Staphylococcal Infections | 2 | 2009 | 391 | 0.110 |
Why?
| | Bacterial Infections | 2 | 2011 | 233 | 0.110 |
Why?
| | Heart Transplantation | 1 | 2020 | 722 | 0.110 |
Why?
| | Hemoglobins | 1 | 2016 | 339 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 787 | 0.110 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 114 | 0.110 |
Why?
| | Confidence Intervals | 1 | 2014 | 317 | 0.100 |
Why?
| | Bacteria, Anaerobic | 1 | 1993 | 22 | 0.100 |
Why?
| | Genital Diseases, Female | 1 | 1993 | 27 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 349 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2014 | 204 | 0.100 |
Why?
| | Population Surveillance | 1 | 2014 | 439 | 0.090 |
Why?
| | Azithromycin | 1 | 2011 | 93 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1500 | 0.080 |
Why?
| | Technology Assessment, Biomedical | 1 | 1989 | 28 | 0.080 |
Why?
| | Young Adult | 3 | 2015 | 12457 | 0.080 |
Why?
| | Daptomycin | 1 | 2009 | 19 | 0.080 |
Why?
| | Intensive Care Units | 1 | 2014 | 737 | 0.080 |
Why?
| | Vancomycin | 1 | 2009 | 78 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 1994 | 838 | 0.070 |
Why?
| | Th1 Cells | 1 | 2009 | 137 | 0.070 |
Why?
| | Pregnancy | 3 | 2016 | 6412 | 0.070 |
Why?
| | Animals | 4 | 2021 | 35404 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 1989 | 392 | 0.070 |
Why?
| | Bacteremia | 1 | 2009 | 194 | 0.070 |
Why?
| | Aged | 5 | 2020 | 22101 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2009 | 481 | 0.060 |
Why?
| | Cytosine | 1 | 2005 | 48 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 30 | 0.060 |
Why?
| | Organophosphonates | 1 | 2005 | 91 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2005 | 92 | 0.060 |
Why?
| | Pregnancy Complications | 1 | 1989 | 493 | 0.060 |
Why?
| | Drug Resistance, Microbial | 2 | 1996 | 69 | 0.060 |
Why?
| | Colorado | 1 | 2014 | 4405 | 0.050 |
Why?
| | Liposomes | 1 | 2005 | 171 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2009 | 593 | 0.050 |
Why?
| | Pneumonia | 1 | 1989 | 619 | 0.050 |
Why?
| | Autopsy | 1 | 2003 | 92 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1000 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2020 | 10221 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 133 | 0.050 |
Why?
| | Oxidation-Reduction | 2 | 2017 | 1031 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 299 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 1058 | 0.050 |
Why?
| | Cholangitis | 1 | 2002 | 20 | 0.050 |
Why?
| | Peritoneal Dialysis, Continuous Ambulatory | 1 | 2001 | 15 | 0.050 |
Why?
| | RAW 264.7 Cells | 1 | 2021 | 49 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 69 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2021 | 159 | 0.040 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2002 | 99 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | Peritonitis | 1 | 2001 | 81 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 83 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 18 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 176 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2002 | 223 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 207 | 0.040 |
Why?
| | Fetal Blood | 1 | 2002 | 318 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2005 | 718 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 611 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2020 | 199 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2020 | 228 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 635 | 0.030 |
Why?
| | Medication Adherence | 1 | 2022 | 561 | 0.030 |
Why?
| | Cytotoxins | 1 | 1994 | 16 | 0.030 |
Why?
| | Caenorhabditis elegans | 1 | 2017 | 296 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1994 | 104 | 0.030 |
Why?
| | Gram-Negative Anaerobic Bacteria | 1 | 1993 | 2 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 376 | 0.030 |
Why?
| | Gram-Positive Bacteria | 1 | 1993 | 44 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2022 | 14525 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 2002 | 1066 | 0.020 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1992 | 123 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1090 | 0.020 |
Why?
| | Macrolides | 1 | 2011 | 60 | 0.020 |
Why?
| | Nasopharynx | 1 | 2011 | 68 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1992 | 148 | 0.020 |
Why?
| | Adolescent | 3 | 2022 | 20415 | 0.020 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1989 | 6 | 0.020 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2009 | 21 | 0.020 |
Why?
| | Obstetric Labor, Premature | 1 | 1989 | 35 | 0.020 |
Why?
| | New York City | 1 | 1989 | 81 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2014 | 353 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 63 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 51 | 0.020 |
Why?
| | Infant Mortality | 1 | 1989 | 106 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 323 | 0.020 |
Why?
| | Interleukin-2 | 1 | 2009 | 437 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 160 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 248 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2009 | 773 | 0.020 |
Why?
| | Risk Factors | 2 | 2009 | 9787 | 0.010 |
Why?
| | Simplexvirus | 1 | 2005 | 80 | 0.010 |
Why?
| | United States | 2 | 2014 | 13906 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2009 | 1110 | 0.010 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 110 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 277 | 0.010 |
Why?
| | Length of Stay | 1 | 1989 | 1127 | 0.010 |
Why?
| | Mice | 1 | 2021 | 16982 | 0.010 |
Why?
| | Bile Duct Diseases | 1 | 2002 | 14 | 0.010 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2002 | 65 | 0.010 |
Why?
| | Antigens, CD34 | 1 | 2002 | 88 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 2002 | 234 | 0.010 |
Why?
| | Drainage | 1 | 2002 | 164 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2378 | 0.010 |
Why?
| | Treatment Failure | 1 | 2002 | 339 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4102 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 326 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 141 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 349 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 7145 | 0.010 |
Why?
| | Graft Survival | 1 | 2002 | 514 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 5434 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 869 | 0.010 |
Why?
| | Chronic Disease | 1 | 2002 | 1723 | 0.010 |
Why?
| | Neutrophils | 1 | 2002 | 1209 | 0.010 |
Why?
| | Lung Diseases | 1 | 2002 | 741 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2001 | 1506 | 0.010 |
Why?
| | Suppuration | 1 | 1992 | 9 | 0.010 |
Why?
| | Catalase | 1 | 1992 | 128 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2104 | 0.010 |
Why?
| | Infant | 1 | 2002 | 8987 | 0.000 |
Why?
| | Child, Preschool | 1 | 2002 | 10487 | 0.000 |
Why?
| | Child | 1 | 2002 | 20882 | 0.000 |
Why?
|
|
Madinger's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|